Note To Reporters and Editors:National Cancer Institute Hosts Session
on New Developments in Nanotechnology

What:

Please join us to discuss new developments
in nanotechnology in cancer. The session will include a review
of nanotechnology, how it is affecting research, and accelerating
the development of new diagnostics and therapies. Speakers
will include NCI leadership, as well as biologists, engineers
and physicians who are members of the NCI Alliance for Nanotechnology
in Cancer, an initiative to accelerate the application of
nanotechnology to cancer research and patient care. Among
the featured speakers will be scientists discussing their
work in delivery, imaging and therapeutics.

If you cannot attend in person, the audio portion of the
media session is available to reporters via a toll-free
conference line at 866-755-5928, conference ID #9241089.
Slides presented during the session can be viewed live,
on-line at http://nihbreeze.cit.nih.gov/nanomedia/.
To access the slides, use the “enter as guest” option.

The session will begin promptly at 12:15 p.m. PDT. Reporters
should dial in and log on 5-10 minutes before the start of
the conference. Following the presentations, an operator
will inform callers that the session is open to questions.
To ask a question, press “*1” on your touchtone phone. You
will hear a tone to indicate your question is pending.

For more information about cancer, please visit the NCI Web site at http://www.cancer.gov or
call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

The National Institutes of Health (NIH) — The Nation's Medical
Research Agency — includes 27 Institutes and Centers and
is a component of the U.S. Department of Health and Human Services.
It is the primary federal agency for conducting and supporting basic,
clinical and translational medical research, and it investigates the
causes, treatments, and cures for both common and rare diseases. For
more information about NIH and its programs, visit www.nih.gov.